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Abstract 
Inter-a-inhibitor (Jal) is a serine protease inhibitor 
present in human plasma. It has a molecular weight of 
about 220 kDa which encompasses 3 chains including 
two heavy chains and one light chain. The light chain, 
known as bikunin, is responsible for the antitryptic ac-
tivity of Jal in the inhibition of various enzymes, such 
as trypsin and chymotrypsin. Under physiologic or cer-
tain pathologic circumstances, several macromolecules 
related to Jal appear in plasma and urine. However, the 
physiologic role of Jal remains unclear. As far as uro-
lithiasis is concerned, two urinary macromolecules relat-
ed to Jal have been isolated and shown to be potent in-
hibitors of calcium oxalate formation. One of these in-
hibitors, uronic-acid-rich protein (UAP), has been iden-
tified and well characterized. The sequence of the first 
18 amino acid residues of UAP is identical with that of 
bikunin. Furthermore, the immunoreaction between 
UAP and Jal antibody using immunoblot analysis was 
positive. UAP isolated from the urine of stone formers 
exhibited less inhibitory activity towards calcium oxalate 
crystalliz.ation than that derived from the urine of healthy 
subjects. This suggests a structural abnormality of the 
inhibitor obtained from stone patients. The organic 
matrix extracted from kidney stones contained a protein 
antigenically related to Jal. We conclude that UAP is 
a member of Jal family taking part in inhibiting calcium 
oxalate crystalliz.ation, and modulating the formation of 
stones in the urinary tract. 
Key Words: Urolithiasis, urine, plasma, calcium oxa-
late, inter-a-inhibitor, uronic-acid-rich protein, bikunin. 
• Address for Correspondence: 
Saeed R. Khan 
Univer sity of Florida, College of Medicine, 
Department of Pathology and Laboratory Medicine, 
Gainesville, FL 32610--0275, USA. 
Telephone number: (352) 392-3574 
FAX number: (352) 392-6249 
E. mail: khan.pathology@mail.health.ufl.edu 
425 
Introduction 
Mammalian blood is a rich source of proteinase in-
hibitors which account for about 10 % by weight of all 
plasma proteins in human [46 , 69]. They constitute the 
third largest group of functional proteins after albumin 
and immunoglobulins. Inter-a-inhibitor (Jal) is one 
among the well characterized human serine plasma pro-
teinase inhibitors. These inhibitors seem to control di-
verse critical events associated with proteolysis that oc-
cur during pathologic circumstances such as cancer, fi-
brinolysis, and inflammation by inhibiting the action of 
various enzymes including neutrophil elastase, cathepsin 
G, and plasmin [20, 28 , 50] . Nevertheless, the physio-
logical function of fol is still not well established. The 
average concentration of fol in plasma of healthy human 
subjects is about 450 mg/I [65]. Low amounts of other 
smaller macromolecules immunologically related to Jal 
are also present in plasma and urine. Their level in-
creases in pathological conditions, suggesting that they 
could be a result of an increase of Jal turnover. Many 
of these macromolecules have been purified and charac-
terized to understand the mechanism of their release and 
the importance of their presence in the body fluids. A 
few years ago, two macromolecules related to fol and 
having the ability to inhibit calcium oxalate (CaOx) crys-
talliz.ation in vitro were isolated from human urine [2, 
63] . 
This paper is written to focus attention on the rela-
tionship between Jal and urolithiasis. We describe here 
Jal and its related proteins, specifically those that may 
be involved in stone formation . 
Structure of fol and its Immunologically 
Related Derivatives (Figure 1) 
Jal is a glycoprotein with a molecular weight of 
about 180-220 kDa. A decade ago, it was thought that 
Jal contained a single polypeptide chain since it showed 
a unique band on sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) in the presence of 
strong reducing agents [41, 51]. However, subsequent 
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Figure 1. Structure oflal and its derivatives according to reference 54. Bikunin is derived from a common precursor 
that codes also for al-microglobulin (al-m). It is present in a free form or complexed with one or two heavy (H) 
chains constituting H2/Bikunin, inter-a-inhibitor (Ial) (Hl + H2 + bikunin), or pre-a-inhibitor (Pal) (H3 + bikunin). 
A glycosaminoglycan (GAG) chain, associated with bikunin, ensures the junction between the different subunits of lal 
and its related proteins. 
-------------------------------------------------------------------------------------------------
data coming from molecular biology techniques demon-
strated the presence of two or three distinct mRNAs cod-
ing for heavy (H) and light (L) chain respectively [11, 
19, 25, 56, 60]. The latter is called bikunin, formerly 
known as urinary trypsin inhibitor, acid-stable trypsin 
inhibitor, the light chain of lal, or HI-30. Bikunin 
originates from a common mRNA that also codes for an-
other protein called al-microglobulin (al-m) [34, 37, 
53, 62, 71]. As soon as they are synthesized, a cleav-
age occurs and both al-m and bikunin are released sepa-
rately [49] . al-m has never been found associated with 
Ial or its related polypeptides [56, 60]. In humans, the 
scission seems to occur at the amino acid sequence Arg-
Val-Arg-Arg immediately preceding the bikunin subunit 
of the precursor [13]. Therefore, these amino acid resi-
dues are missing in the final product. Yet, the mecha-
nism and conditions under which the precursor is broken 
away remain elusive. Now, it is recognized that Ial 
comprises two heavy chains (Hl: 78 kDa and H2: 85 
kDa) and bikunin (45 kDa) [10, 38, 45, 52]. The genes 
of these chains are located on the chromosome 3p21.1-
p21. 2, 10p14-pl5, and 9q32-q34 respectively [19, 59]. 
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Bikunin is also present in a free form in plasma and 
urine [54]. Interestingly, the three chains are held to-
gether in unique complex by way of a carbohydrate 
chain [32, 38]. Bikunin contains a N-linked oligosaccha-
ride chain and an O-linked oligosaccharide chain at-
tached to Asn45 and Ser10 respectively [25, 29]. The 
latter was further demonstrated to be a glycosaminogly-
can (GAG) [17]. Several studies demonstrated that 
chondroitinase and hyaluronidase can split lal into heavy 
and light chains [8, 9, 61]. Recent results confirmed 
that the GAG chain covalently cross-linked the subunits 
oflal [40]. 
Another protein related to lal has also been found 
and named pre-a-inhibitor (Pal) [22]. It is made of bi-
kunin, similar to that of Ial and a heavy chain (H3: 85 
kDa) coded by another mRNA different from those de-
scribed earlier for Ial. This demonstrated that Pal con-
stituted a protein distinct from Ial and not derived from 
it by proteolysis [22]. A protein consisting of H2 and 
bikunin is also present in the plasma [18, 21, 54]. The 
nature of the cross-linking between the two polypeptide 
chains of this protein appears similar to that found in 
Inter-a-inhibitor in urolithiasis 
Pal. In all polypeptide complexes, Ial, H2/bikunin, or 
Pal, bikunin seems to be responsible for their antitryptic 
activity by inhibiting various enzymes, particularly tryp-
sin and chymotrypsin [20, 28, 50) . 
When Ial and bikunin are submitted to a prolonged 
digestion with trypsin, they release fragments of a mo-
lecular weight of 14 and 8 kDa named HI-14 and Hl-8, 
respectively [30, 72). The amino acid composition of 
bikunin and Hl-14 are identical indicating that HI-14 is 
the peptidic chain of bikunin and large carbohydrate 
moieties should be responsible for the molecular weight 
of 45 kDa of the native form of bikunin. Therefore, HI-
14 and HI-8 may be products of Ial or bikunin which 
are fragmented during purification or in the presence of 
enzymes like trypsin. 
Biosynthesis and Localization of fol 
and its Derivatives (Table 1) 
Ial is synthesized mainly in the liver and excreted 
in plasma [10, 62). This finding was confirmed at the 
molecular level. Indeed, the mRNA encoding for the 
Ial subunits was found expressed only in the liver [56). 
Nevertheless, the expression of the gene encoding for 
the heavy chain H3 has also been observed in the brain 
[55]. By using dot blot analysis, the mRNA encoding 
for the precursor a 1-microglobulin/bikunin was found in 
rat at high level in the liver and kidney, low in the brain 
and testis [33). Further studies by the same authors 
however, confirmed its synthesis in the liver only [37). 
In pig, the expression of mRNA of this precursor was 
observed at high level in the liver and, at a low level, in 
the stomach [67). 
The immunochemical distribution of Ial and its de-
rivative fragments in different organs has been investi-
gated (Table 1). Under normal conditions, Ial immuno-
reactivity was found in the liver, kidney, testis, gross 
intestine, cutis and brain [15, 73, 74). Surprisingly, the 
immunoreaction was also detected in cultured fibroblasts 
[14) and human mast cells [44). Also using al-micro-
globulin antibody, a positive immunoreaction was ob-
served in human lymphocytes and macrophages [33) . 
The presence of Ial related proteins in the urinary tract 
has been specially investigated [44) . Ial immunoreac-
tivity was found to be exclusively present in renal proxi-
mal tubules due to the reabsorption of bikunin by this 
segment of nephron. Ial immunoreactivity was also de-
tected in human mast cells in the connective tissue of a 
bladder papilloma and in the rat bladder epithelium [ 44). 
Physiological Role of fol and its Related Proteins 
The presence of Ial in various tissues suggests that 
it may fulfill different physiological functions. So far, 
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Table l. Distribution of Ial and its derivatives in 
normal tissues. 
Type of Method References 
tissue 
Liver Immunohistology [15) 
mRNA analysis [37·, 55, 56, 67.) 
Lung Elisa [15) 
Immunohistology [73) 
Kidney Immunohistology [15, 44, 73, 74] 
Brain Immunohistology [15, 73, 74] 
Stomach lmmunohistology [73, 74] 
mRNA analysis [67.] 
Testis lmmunohistology [15] 
•Distribution of a 1-microglobulin/Bikunin mRN A 
---------------------------------
however, these roles have not been resolved. IaI is es-
pecially sensitive to some enzymes such as elastase and 
cathepsin G which are activated during several diseases 
including cancer, inflammation, and renal failure . Due 
to their smaller size, proteins obtained from Ial turnover 
may be able to diffuse throughout the affected tissues 
and may contribute to the cells' protection against pro-
teolysis. Nevertheless, Ial accounts for less than 5% of 
the total trypsin inhibitory activity [6, 57] which does 
not favor such a protective role. Moreover, the results 
showed no significant consumption of Ial during the in-
flammation process, although proteins related to IaI 
were present [58]. However, these results were con-
tested in other studies [26, 45]. 
McKeehan et al. [39] isolated from human hepato-
ma cells two endothelial cell growth factors structurally 
similar to pancreatic secretory trypsin inhibitor and 
bikunin. Both proteins are absent or present in low 
amounts in normal plasma and urine. They stimulate 
endothelial cell growth and their concentrations were 
increased during inflammation and cancer. These find-
ings suggest that Ial and their related proteins may be 
involved in neovascularii.ation and desmoplasia, associ-
ated with tumor and tissue damage process. 
Lastly, S0rensens work [63] and particularly our 
studies [2] demonstrated that a glycoprotein related to 
Ial, most probably a urinary bikunin, is a potent inhibi-
tor of CaOx crystal growth in vitro and may inhibit and 
reduce the formation of CaOx crystals in urinary tract. 
Relationship of fol and its Derivatives to Urolithiasis 
S0rensen et al. [63] isolated a protein from normal 
human urine using two anion exchange chromatography 
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Table 2. Comparison of physico-chemical properties of S0rensens protein, uronic-acid-rich protein (UAP), and urinary 
bikunin. 
Proteins Molecular CaOx growth 
weight (kDa) inhibitory activity 
Sorensen's protein 40 +++ 
UAP 35 +++ 
Urinary bikunin 45 + 
steps (on DEAE-Sephacel and Mono Q column) and one 
affinity chromatography (vinylsulfone agarose). The 
protein exhibited quite the same characteristics as uri-
nary bikunin: molecular weight in SDS-PAGE: 40 kDa, 
in gel filtration: 67 kDa, identical N-terminal sequence, 
and presence of uronic-acids. The authors found that 
this Icd fragment was a potent inhibitor of CaOx crystai 
growth and stated that it is the only protein which might 
have an inhibitory activity in the urine. By chondroi-
tinase digestion, the uronic acids were removed but the 
inhibitory capacity of the protein remained. Moreover, 
pronase digestion had no effect upon its inhibitory capac-
ity and the authors considered that this data might be ex-
plained by the antiprotease activity of the inhibitor [63]. 
Unfortunately, further characterization of this inhibitor 
has so far not been reported. 
In an attempt to find another CaOx inhibitor, we 
fractionated human urinary macromolecules using three 
chromatographic procedures including DEAE-Sephacel 
gel followed by Sephacryl S-300 chromatography, and 
finally Mono Q column using an FPLC system. We 
were able to isolate and purify a macromolecule with a 
molecular weight of 35 kDa as estimated by SDS-P AGE 
[2]. The protein showed a potential activity to slow the 
rate of CaOx crystal growth efficiently. Moreover, as 
described in detail in reference [2], its crystallization 
inhibitory activity was greater than that of nephrocalcin 
or nephrocalcin-like macromolecule considered, at the 
time, the principal urinary inhibitor of CaOx crystalliza-
tion [42]. The inhibitor was named uronic-acid-rich pro-
tein (UAP) due to its uronic acid contents. The molecu-
lar characteristics of UAP indicated structural similari-
ties with bikunin. The sequence of the first 18 amino 
acid residues of the protein was identical with that of 
bikunin [l, 4]. Moreover, by using a polyclonal fol an-
tibody by immunoblotting analysis, a positive immuno-
reaction was observed confirming the close relationship 
between UAP and fol [l]. 
UAP was also isolated from rat urine and compared 
to that isolated from human urine [l] . Both showed 
identical amino acid composition, similar amino acid se-
quence, and similar crystallization inhibitory activity. 
UAP was assayed on CaOx crystal growth model before 
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Effect of pronase on Effect of chondroitinase 
CaOx inhibition 
No effect U ronic acid removed 
Activity destroyed Produces a protein of 20 kDa 
Activity destroyed Produces a protein of 20 kDa 
and after treatment with pronase, chondroitinase AC, 
and hyaluronidase as described by S0rensen et al. [63]. 
Our data demonstrated that chondroitinase and hyalu-
ronidase had no effect on CaOx growth inhibitory ac-
tivity of UAP, but yielded a protein with a molecular 
weight of 20 kDa [4]. This finding suggests that UAP 
comprises a large giycosaminoglycan chain responsible 
for its molecular weight at 35 kDa. In contrast to 
S0rensens study, pronase treatment degraded the total 
inhibitory activity of UAP suggesting that the inhibitor 
isolated by us is different from the one purified by 
S0rensen et al. [63]. A comparison of physico-chemical 
proprieties of these proteins is shown in Table 2. We 
hypothesize that both UAP and S0rensens protein may 
exist in urine as separate entities or they may be the 
same protein purified by slightly different methods. 
Is UAP Bikunin? 
The results of amino acid sequence and immunoblot-
ting analysis suggest that UAP is a protein related to fol 
family and could be bikunin. To clarify this relation-
ship, in our recent study (Atmani et al., Eur. J. Bio-
chem., in press), both UAP and urinary bikunin were 
isolated and purified from human urine. Their CaOx 
growth inhibitory activity was assayed before and after 
pronase treatment. The inhibition assay consists in using 
a mixture of 1 ml supersaturated solution of CaCl2 (2 
mmol/1 in Tris 0.05 mol/l, NaCl 0.15 mol/1, pH 7 .3) in 
the presence of [45 Ca]CaC12 and 1 ml ammonium oxa-
late (2 mmol/l in Tris 0.05 mol/1, NaCl 0.15 mol/l, pH 
7. 3). The tubes containing proteins were compared with 
those without added proteins. At the end of the assay, 
tubes were centrifuged at 2000 g for 5 minutes and 0.5 
ml of supernatant was withdrawn for radioactivity deter-
mination in a liquid scinti llation counter. The inhibitory 
activity was determined before and after enzymatic di-
gestion. The results shown in Figure 2 demonstrate that 
UAP exhibited a strong CaOx growth inhibitory activity 
while urinary bikunin was less inhibitory. The CaOx 
inhibitory activity of both proteins disappeared after 
pronase digestion. Structurally, UAP and urinary bi-
kunin have many similarities. Their molecular weight 
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Figure 2. Calcium oxalate growth inhibitory activity of 
UAP and urinary bilcunin before (a, c) and after treat-
ment (b, d) with pronase respectively. 
is 35 and 45 kDa respectively. They have similar amino 
acid composition and similar amino acid sequence of 
first 18 residues. Furthermore, they are immunological-
ly related to fol. However, functionally they appear 
different. A comparison of physico-chemical proprieties 
of UAP and urinary bilcunin is reported in Table 2. 
As we have reported above, bikunin is present in 
free form or attached to different complexes related to 
fol. The free form can easily pass into urine through 
glomeruli due to its low molecular weight. Metabolism 
oflal or its related proteins (enzymatically for instance) 
may yield another form of bikunin. The latter may be 
modified during this process and present some differ-
ences compared to the preexisting free form of bikunin. 
Furthermore, the isolation of bikunin with different mo-
lecular weights, has been reported by several investiga-
tors [7, 9, 16, 23, 61]. These discrepancies may be due 
to differences in various technical procedures used in the 
isolation and purification of proteins. The carbohydrate 
content of the protein and the presence of a GAG chain 
that can modify its electrophoretic mobility should be 
taken into consideration since many results are still in 
disagreement. However, it has been reported that the 
carbohydrate chain does not contribute to CaOx inhibi-
tory activity of proteins related to fol [2, 63]. Experi-
ments are in progress to clarify this matter. 
Nephrocalcin with a molecular weight of about 14 
kDa, is one of the well-known urinary inhibitors of 
CaOx crystallization [42]. So far, the amino acid se-
quence of this inhibitor remains unknown. We isolated 
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a human urinary protein which we named nephrocalcin-
like [2] due to its biochemical similarities with nephro-
calcin described by Nakagawa et al. [42]. The molecu-
lar weight of the protein was about 16 kDa, it was able 
to bind to Tamm-Horsfall protein, and it showed an im-
portant inhibitory activity toward CaOx crystallization. 
However, this inhibitory activity was lower than that of 
UAP. Unfortunately, at that time, we did not determine 
its amino acid sequence. In a recent study, Ryalls 
group [66] reported the partial amino acid sequence of 
a protein claimed to be nephrocalcin. It showed an 
identity with HI-14, a fragment ofbikunin. As we men-
tioned earlier, prolonged digestion of fol or bikunin with 
trypsin, results in the production of two peptides, Hl-14 
and HI-8 . Consequently, HI-14 is not a physiological 
product. Moreover, many features of nephrocalcin do 
not match with Hl-14 fragment. For instance, nephro-
calcin has 2-3 ')'-carboxyglutamic acid (Gla) residues and 
is synthesized in kidney, but Hl-14 does not contain Gla 
and is not produced in kidney. Therefore, the results 
obtained by Ryalls group remain speculative. 
fol and its Related Proteins in Lithiasis Disease 
Many reports indicate that urine of stone formers 
contains macromolecules that inhibit CaOx crystal for-
mation, but not efficiently as the same inhibitors found 
in the urine of normals [3 , 27 , 43]. With regards to 
fol, its plasma concentration was reduced during various 
pathologic conditions including renal failure [24, 45 , 46, 
68] . Simultaneously, urinary bilcunin concentration was 
increased suggesting an enhancement of fol turnover. 
Although, these findings were not confirmed in other 
studies suggesting that fol and its related proteins could 
be synthesized in separate pathways [13, 47, 58]. Ac-
cordingly, since UAP is related to fol, may be its excre-
tion is increased in the urine of patients with renal dis-
ease. Thereby, an increase in Ca Ox growth inhibitory 
activity is anticipated. Unfortunately, this was not the 
case, suggesting that UAP obtained from stone formers 
may be structurally abnormal and does not inhibit crystal 
precipitation efficiently. Accordingly, we have isolated 
UAP from the urine of stone formers and its inhibitory 
activity was compared to that purified from the urine of 
healthy subjects [3]. The results demonstrated that UAP 
obtained from stone patients exhibited less inhibitory ac-
tivity. Partial structure of this glycoprotein showed that 
it contained less sialic acid than that of normals [3]. 
fol Related Proteins in Stones 
Regardless of mineral composition, all urinary 
stones contain an organic material refereed to as matrix 
protein [35, 36]. The latter represents about 2-5 % by 
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weight and consists predominantly of proteins [12]. Its 
role in the formation of urinary stones remains a subject 
of research. To better understand this role, many inves-
tigators attempted to analyze proteins extracted from uri-
nary stones. Unfortunately, few works were devoted to 
a search for fol and its related peptides and to quantify 
them. Petersen et al. [ 48] have found hemoglobin and 
two serine proteases in the extract of CaOx kidney 
stone. A protease inhibitor, al-antitrypsin, has been 
extracted and quantified suggesting that some stones are 
in contact with blood during their development [70]. 
Hoyer [31] has extracted several proteins from CaOx 
monohydrate stones and quantified them. His results 
showed that uropontin, or osteopontin, constituted the 
major protein in the extract (90 µg/100 mg). Tamm-
Horsfall protein, albumin, and fol fragment represent 
less than 10 µg/100 mg of stones. Recently, in our lab-
oratory we identified proteins extracted from CaOx crys-
tals produced in vitro in human urine by adding sodium 
oxalate [5]. Among the proteins, we detected a frag-
ment of fol, which could be bikunin, but in lesser 
amounts compared to prothrombin Fl and osteopontin. 
More experiments are in progress. 
Concluding Remarks 
It seems that UAP is biochemically similar to biku-
nin, the light chain of fol. But functionally these two 
proteins appear different. fol becomes a family of pro-
teins involved in modulating calcium oxalate crystalliza-
tion and stone formation. Another plasma protein, the 
F 1 fragment of prothrombin has also been implicated in 
calcium oxalate stone formation [64]. Apparently, the 
crystallization of calcium oxalate is modulated by a vari-
ety of macromolecules including many plasma proteins. 
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Discussion with Reviewers 
B. Hess: How do the authors explain the suggested re-
absorption of fol in the proximal tubule, i.e., how does 
a protein with a molecular weight of 180-220 kDa get 
across the tubular membrane into the tubular fluid? 
Reviewer VII: The question of whether bikunin/UAP 
(or fol) is synthesized in the kidney, or is merely fil-
tered at the glomerulus is not directly addressed. Do the 
authors have any data to define more precisely the 
nature of the fol reactivity? 
Authors: fol is mainly synthesized in the liver and se-
creted in plasma. Recent work studying the expression 
of mRNA coding for fol confirmed its exclusive synthe-
sis in the liver [55]. The presence of a positive fol 
immunoreactivity in kidney is due to the presence of bi-
kunin which has a molecular weight in a range of 35-45 
kDa, and can easily pass through the glomerular filters, 
thus, it can be recognized by fol polyclonal antibody. 
B. Hess: Similarity of nephrocalcin (NC) and Hl-14 of 
fol/bikunin: nephrocalcin contains Gia; what is the Gia-
content of Hl-14 of fol/bikunin? 
Authors: Nephrocalcin is known to have 2-3 Gia resi-
433 
dues. However, Hl-14 or any protein related to fol 
does not have any Gia residue. Interestingly, in a recent 
work, Tang et al. [66) reported that NC is Hl-14 by us-
ing similar techniques described by Nakagawa to isolate 
NC. The authors suggested that NC was contaminated 
by other proteins containing Gia, like prothrombin Fl, 
to explain the presence of these residues in the prepara-
tion of NC. Nonetheless, another feature of NC is it is 
synthesized in kidney, but Hl-14 is not. Therefore, sim-
ilarity or identity of NC to Hl-14 remains speculative 
and needs confirmation by, e.g., using NC antibody. 
B. Hess: It should be acknowledged that there are cer-
tain requirements for an inhibitor/modifier to be of clini-
cal significance for calcium stone formation, such as: (1) 
abundance in urine, (2) occurrence of calcium binding 
sites in the molecule, (3) structural and functional abnor-
malities or significantly reduced excretion in active stone 
formers versus healthy people, and (4) possibly some 
therapeutic implications, i.e., altering physico-chemical 
conditions of urines, modifying the diet or prescribing 
certain drugs should improve the functional status of a 
given macromolecule towards more inhibition of crystal-
lization, mainly crystal aggregation. 
Authors: In this paper, we do not attempt to describe 
UAP as a superinhibitor to be considered and the others 
to be discarded. In the paper where UAP was described 
for the first time [2], we pointed out that one inhibitor 
alone cannot be responsible for the total urinary inhibi-
tory activity. Moreover, in a second paper [3], we re-
ported that UAP extracted from the urine of stone form-
ing subjects was less inhibitory compared to that isolated 
from the urine of healthy persons. We suggested that 
this diminution does not account for the total urinary 
inhibitory activity, but that other protein inhibitors also 
may be defective. 
M. Daudon: The authors suggest that variation in uri-
nary excretion of fol related proteins may occur in vari-
ous pathological conditions responsible for an increased 
excretion of bikunin. Do the authors have some infor-
mation about the normal range of UAP and bikunin ex-
cretion in human urine? 
Authors: The normal range of urinary excretion of fol 
related proteins is about 2 to 10 mg/day according to the 
method used [77, 78). This excretion can be enhanced 
to 50-100 fold or even more in certain pathological 
conditions such as cancer [75, 76). 
M. Daudon: How can the authors explain the weaker 
inhibitory activity of UAP reported in this paper as 
compared to that reported in a previous paper [4]? 
Authors: The weaker inhibitory activity of UAP in this 
study is not significant compared to that reported in the 

